J
Joelle Guilhot
Researcher at French Institute of Health and Medical Research
Publications - 159
Citations - 8016
Joelle Guilhot is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Imatinib mesylate & Myeloid leukemia. The author has an hindex of 38, co-authored 158 publications receiving 6877 citations. Previous affiliations of Joelle Guilhot include University of Poitiers.
Papers
More filters
Journal ArticleDOI
Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib: A report from the I-CML-Ped Study.
Deborah Meyran,Arnaud Petit,Joelle Guilhot,Meinolf Suttorp,Petr Sedlacek,Eveline S. J. M. de Bont,Chi Kong Li,Krzysztof Kałwak,Birgitte Lausen,Srdjana Culic,Barbara De Moerloose,Andrea Biondi,Frédéric Millot +12 more
TL;DR: Children evolving to AP or BP under treatment with imatinib have a very poor prognosis with an overall survival under 50%, much worse than children with advanced phase at diagnosis.
Journal ArticleDOI
Loss Of Major Molecular Response As a Trigger For Restarting Tyrosine Kinase Inhibitor Therapy In CP-CML Patients Who Have Stopped Imatinib After Durable Undetectable Minimal Residual Disease
Aude Charbonnier,Pascale Cony-Makhoul,Philippe Agape,Franck E. Nicolini,Bruno Varet,Martine Gardembas,Gabriel Etienne,Delphine Rea,Lydia Roy,Martine Escoffre-Barbe,Agnès Guerci-Bresler,Michel Tulliez,Stéphane Prost,Marc Spentchian,Jean-Michel Cayuela,Josy Reiffers,Jean-Claude Chomel,Ali G. Turhan,Joelle Guilhot,François Guilhot,Francois-Xavier Mahon +20 more
TL;DR: Loss of major molecular response (MMR) is a practical and safe criterion for restarting therapy in CML patients with prolonged CMR and could be used for future discontinuation studies.
Journal ArticleDOI
Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).
François Guilhot,Lydia Roy,Joelle Guilhot,Tillmann Krahnke,Agnès Guerci,Brian J. Druker,Richard A. Larson,S. O'Brien,Charlene So,Giorgio Massimini +9 more
TL;DR: This historical comparison shows that for first line therapy for newly diagnosed CP CML, imatinib is superior to prolonged therapy with IFN/Ara-c for rate of MCyR, CCyr, PFS and overall survival.
Journal ArticleDOI
Advanced Phases at Diagnosis of Childhood Chronic Myeloid Leukemia : The Experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study)
Frédéric Millot,Joelle Guilhot,Meinolf Suttorp,Natacha Maledon,Meral Günes Adalet,Petr Sedlacek,Eveline S. J. M. de Bont,Chi Kong Li,Krzysztof Kałwak,Birgitte Lausen,Gordana Jakovljević,Michael Dworzak,Andrea Hraskova,Barbara De Moerloose,Roula Farah,Andrea Biondi,André Baruchel +16 more
TL;DR: The data indicates that the frequency of advanced phases at diagnosis of CML is similar in children and in adults but with a predominance of lymphoid phenotype in children in blastic phase compared to adult population.
Journal ArticleDOI
Topoisomerase II α and telomerase expression in papillary thyroid carcinomas
TL;DR: Enhanced Topo II α expression in PTCs from patients less than 40 years old suggests that this age group might benefit from Topo I inhibitor chemotherapy.